ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Although the pathway of Lyn activation seems to be independent of BCR-ABL1 [28], it would be worthwhile to explore the possible interaction between Lyn and AQP5 in CML cells and see how AQP5 ablation affects the growth of imatinib mesylate-resistant primary CML cells.